Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study.
Legendre
C
C
Transplantation Service, Necker Hospital, Paris, France.
Ducloux
D
D
Ferroni
A
A
Chkoff
N
N
Valette
C
C
Geffrier
C
C
Rouzioux
C
C
Kreis
H
H
D000212:Acyclovir / Q000627:therapeutic use*; D000328:Adult; D016022:Case-Control Studies; D003404:Creatinine / Q000097:blood; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000473:pathology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D014019:Tissue Donors
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003404:Creatinine; D000212:Acyclovir